Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Authors
Yang, James Chih-HsinHirsh, Vera
Schuler, Martin
Yamamoto, Nobuyuki
O'Byrne, Kenneth J
Mok, Tony S K
Zazulina, Victoria
Shahidi, Mehdi
Lungershausen, Juliane
Massey, Dan
Palmer, Michael
Sequist, Lecia V
Affiliation
James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Martin Schuler, West German Cancer Center, University Duisburg-Essen, Essen; Juliane Lungershausen, Boehringer Ingelheim GmbH, Ingelheim, Germany; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka, Japan; Kenneth J. O'Byrne, St James' Hospital, Dublin, Ireland; Tony S.K. Mok, State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong; Victoria Zazulina, Mehdi Shahidi, and Dan Massey, Boehringer Ingelheim Limited, Bracknell; Michael Palmer, Keele University, Keele, United Kingdom; and Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA.Issue Date
2013-09-20Keywords
LUNG CANCERQUALITY OF LIFE
MeSH
AdenocarcinomaAntineoplastic Combined Chemotherapy Protocols
Cisplatin
Glutamates
Guanine
Humans
Lung Neoplasms
Mutation
Neoplasm Staging
Quality of Life
Quinazolines
Receptor, Epidermal Growth Factor
Treatment Outcome
Metadata
Show full item recordCitation
Yang JCH et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.2013, 31 (27):3342-50Journal
Journal of clinical oncology : official journal of the American Society of Clinical OncologyDOI
10.1200/JCO.2012.46.1764PubMed ID
23816967Abstract
Patient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed.Item Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2012.46.1764
Scopus Count
Collections
Related articles
- Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
- Authors: Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M
- Issue date: 2013 Sep 20
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
- Authors: Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV
- Issue date: 2015 Feb
- Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
- Authors: Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC
- Issue date: 2013 Feb
- [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
- Authors: Sárosi V, Balikó Z
- Issue date: 2014 Dec
- Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
- Authors: Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N
- Issue date: 2015 Sep